LACTIC ACID BACTERIAL STRAINS
A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli ; (ii) the ability to exhibit antimicrobial activity against S. enteritidis ; (iii) the ability to suppress inflammation in IPEC cells induced by 12-O-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis ; (v) the ability to block the attachment or invasion of IPEC cells by E. coli ; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes. Further aspects of the invention relate to compositions comprising said bacterial strains, and therapeutic uses of said bacterial strains.
1 .- 31 . (canceled)
32 . A pharmaceutical composition comprising at least 10 3 colony forming units (CFU) of at least one Lactobacillus bacteria strain, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein the at least one Lactobacillus bacteria strain comprises a 16S rRNA gene sequence with at least 95% sequence identity to a 16S rRNA gene sequence selected from the group consisting of SEQ ID NOs 10, 11, 13, and 14, as determined by a sequence alignment performed using BLAST, and wherein the pharmaceutical composition is a solid formulation.
33 . The pharmaceutical composition of claim 32 , wherein the pharmaceutical composition is lyophilized.
34 . The pharmaceutical composition of claim 32 , wherein the pharmaceutical composition is encapsulated in one or more capsules.
35 . The pharmaceutical composition of claim 32 , wherein the pharmaceutical composition further comprises a preservative or stabilizer.
36 . The pharmaceutical composition of claim 35 , wherein the preservative comprises sodium benzoate, sorbic acid, or esters of p-hydroxybenzoic acid.
37 . The pharmaceutical composition of claim 32 , wherein the pharmaceutical composition comprises from about 10 3 to about 10 11 colony forming units (CFU) of the at least one Lactobacillus bacteria strain per gram of the pharmaceutical composition.
38 . The pharmaceutical composition of claim 32 , wherein the at least one Lactobacillus bacteria strain exhibits at least one characteristic selected from the group consisting of:
(i) antimicrobial activity against E. coli;
(ii) antimicrobial activity against S. enteritidis;
(iii) suppression of inflammation in intestinal pig epithelial cells (IPEC) induced by 12-O-tetradecaboylphorbol-13-acetate (PMA);
(iv) an ability to block the adherence or invasion of the IPEC by S. enteritidis;
(v) an ability to block the adherence or invasion of the IPEC by E. coli ; and
(vi) absence of antibiotic resistance to an antibiotic selected from the group consisting of ampicillin, cefotaxime, chloramphenicol, erythromycin, gentamicin, tetracycline, vancomycin, metronizadole, nalidixic acid, and kanamycin.
39 . The pharmaceutical composition of claim 38 , wherein the at least one Lactobacillus bacteria strain exhibits at least two characteristics selected from the group of claim 38 .
40 . The pharmaceutical composition of claim 38 , wherein the at least one Lactobacillus bacteria strain exhibits at least three characteristics selected from the group of claim 38 .
41 . The pharmaceutical composition of claim 32 , wherein the at least one Lactobacillus bacteria strain is of a species selected from the group consisting of Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus plantarum, Lactobacillus paraplantarum, Lactobacillus gasseri, Lactobacillus pentosus, Lactobacillus helveticus, Lactobacillus acidophilus, Lactobacillus vaginalis, Lactobacillus mucosae, and any combinations thereof.
42 . A method of treating an intestinal disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising at least at least 10 3 colony forming units (CFU) of at least one Lactobacillus bacteria strain, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein the at least one Lactobacillus bacteria strain comprises a 16S rRNA gene sequence with at least 93% sequence identity to a 16S rRNA gene sequence selected from the group consisting of SEQ ID NOs 10, 11, 13, and 14, as determined by sequence alignment performed using BLAST, and wherein the pharmaceutical composition is a solid formulation in unit dose form.
43 . The method of claim 42 , wherein the intestinal disorder is selected from the group consisting of salmonellosis , irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), functional dyspepsia, functional constipation, functional diarrhea, functional abdominal pain, functional bloating, Epigastric Pain Syndrome, Postprandial Distress Syndrome, Crohn's disease, ulcerative colitis, gastroesophageal reflux disease (GERD), necrotizing enterocolitis, and any combination thereof.
44 . The method of claim 42 , wherein the administering is oral.
45 . The method of claim 42 , wherein the subject is a human.
46 . The method of claim 42 , wherein the at least one Lactobacillus bacteria strain is of a species selected from the group consisting of Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus plantarum, Lactobacillus paraplantarum, Lactobacillus gasseri, Lactobacillus pentosus, Lactobacillus helveticus, Lactobacillus acidophilus, Lactobacillus vaginalis, Lactobacillus mucosae, and any combinations thereof.
47 . A method of improving intestinal microbiota in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising at least at least 10 3 colony forming units (CFU) of at least one Lactobacillus bacteria strain, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein the at least one Lactobacillus bacteria strain comprises a 16S rRNA gene sequence with at least 95% sequence identity to a 16S rRNA gene sequence selected from the group consisting of SEQ ID NOs 10, 11, 13, and 14, as determined by sequence alignment performed using BLAST, and wherein the pharmaceutical composition is a solid formulation.
48 . A method of improving growth in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising at least at least 10 3 colony forming units (CFU) of at least one Lactobacillus bacteria strain, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein the at least one Lactobacillus bacteria strain comprises a 16S rRNA gene sequence with at least 95% sequence identity to a 16S rRNA gene sequence selected from the group consisting of SEQ ID NO 41, as determined by sequence alignment performed using BLAST, and wherein the pharmaceutical composition is a solid formulation.
49 . The method of claim 48 , wherein the subject comprises an early-weaned animal.
50 . The method of claim 48 , wherein the subject comprises a sheep, a goat, a cow, a pig, a horse, a cat, a dog, a turkey, a duck, a chicken, a fish, or a crustacean.
51 . The method of claim 48 , wherein the improving growth comprises gaining weight.